Abstract
Efalizumab is therapeutically effective in moderate to severe plaque psoriasis. Rebound after discontinuing therapy affects approximately 14% of patients, while erythroderma occurs in less than 1% of the treated population. In this case report, we describe two non-responding patients with severe plaque psoriasis who developed erythroderma after treatment was ceased. Non-responders are more likely to suffer from rebound. This article emphasizes the importance of close monitoring of non-responders to efalizumab after discontinuance of treatment.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Dermatitis, Exfoliative / etiology*
-
Dermatitis, Exfoliative / physiopathology
-
Follow-Up Studies
-
Humans
-
Male
-
Middle Aged
-
Monitoring, Physiologic
-
Psoriasis / diagnosis
-
Psoriasis / drug therapy*
-
Risk Assessment
-
Severity of Illness Index
-
Substance Withdrawal Syndrome / etiology*
-
Substance Withdrawal Syndrome / physiopathology
-
Time Factors
-
Treatment Failure
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
efalizumab